[Two decades later, the polypill revisited].

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Public Health

Background:

• The Polypill, a combination drug for cardiovascular disease prevention, was introduced with high expectations.
• Two decades later, its widespread adoption and clinical impact remain subjects of ongoing evaluation.

Purpose of the Study:

• To critically assess the fulfillment of the Polypill's initial promises.
• To review the evidence regarding its long-term effectiveness and safety profile.
• To examine challenges in regulatory approval and potential for over-the-counter status.

Main Methods:

• Review of existing clinical trial data and post-marketing surveillance studies.
• Analysis of the pharmacological rationale and composition variability of different Polypill formulations.
• Evaluation of regulatory requirements for combination drug approval.

Main Results:

• Polypill effectiveness is still debated, with insufficient long-term data in healthy populations.
• Concerns persist regarding long-term adverse effects, especially from aspirin, in individuals without established cardiovascular disease.
• Variable Polypill compositions raise questions about optimal formulation and component relevance.
• Regulatory hurdles exist, requiring demonstration of individual component benefit and contribution.

Conclusions:

• The Polypill's advantages do not clearly outweigh its disadvantages, particularly for primary prevention in healthy individuals.
• Its validation by regulatory authorities is challenging given current evidence.
• Reclassifying the Polypill as an over-the-counter drug is premature and potentially unsafe due to its target population and safety profile.